Effect of rosiglitazone and ramipril on macrovasculopathy in patients with type 2 diabetes: needs longer treatment and/or higher doses?

Sayeeda Rahman, Aziz Al-Shafi Ismail, Shaiful Bhari Ismail, Nyi Nyi Naing, Abdul Rashid Abdul Rahman, Sayeeda Rahman, Aziz Al-Shafi Ismail, Shaiful Bhari Ismail, Nyi Nyi Naing, Abdul Rashid Abdul Rahman

Abstract

Introduction: The aim of the study is to investigate whether standard doses of rosiglitazone (4 mg/daily) and ramipril (5 mg/daily) can reverse pre-clinical macrovasculopathy in newly diagnosed never treated type 2 diabetes (T2DM) patients.

Methods: In this randomized, double-blind, placebo-controlled study, 33 T2DM patients were randomized to rosiglitazone (4 mg/daily) or ramipril (5 mg/daily) or placebo for 1 year. Hemodynamic variables were measured at 3 treatment phases and pulse wave velocity (PWV) and augmentation index (AI) were measured throughout the treatment period.

Result: In diabetic patients, PWV (P = 0.037) and AI (P = 0.005) with ramipril and AI (P < 0.001) with rosiglitazone were significantly reduced during overall treatment period from the baseline; however, these differences were not significant in comparison to placebo.

Discussion and conclusion: The present study showed that treatment with standard doses of rosiglitazone and ramipril are not adequate to reverse pre-clinical vasculopathy in T2DM. The lack of benefit in newly diagnosed T2DM may be because of the relatively short-term intervention and/or the use of lower doses of rosiglitazone/ramipril. Further trials are needed for a longer period of time, possibly with higher doses, to show whether rosiglitazone/ramipril can reverse pre-clinical vasculopathy in T2DM (ClinicalTrials.gov number, NCT00489229).

Keywords: diabetic vasculopathy; ramipril; rosiglitazone.

Figures

Figure 1
Figure 1
Estimated marginal means of PWV and AI in type 2 diabetes between treatment with rosiglitazone, ramipril and placebo from base line overtime. With ramipril PWV (P = 0.037) and AI (P = 0.005) and with rosiglitazone AI (P < 0.001) were significantly reduced during overall treatment period from the baseline. Abbreviations: AI, augmentation index; PWV, pulse wave velocity.

References

    1. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care. 1993;16(2):434–444.
    1. Rahman S, Rahman T, Ismail AA, Rahman ARA. Diabetes-associated macrovasculopathy: pathophysiology and pathogenesis. Diab Obes Metab. 2007;9(6):767–780.
    1. Shargorodsky S, Wainstein G, Gavish E, Leibovitz Z, Matas D, Zimlichman R. Treatment with rosiglitazone reduces hyperinsulinemia and improves arterial elasticity in patients with type 2 diabetes mellitus. Am J Hyperten. 2003;16(8):617–622.
    1. Pistrosch F, Passauer J, Fischer S, Fuecker K, Hanefeld M, Gross P. In Type 2 diabetes rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care. 2004;27(2):484–490.
    1. Langenfeld MR, Forst T, Hohberg C, et al. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes: Results from a controlled randomized study. Circulation. 2005;111(19):2525–2531.
    1. Watanabe I, Tani S, Anazawa T, Kushiro T, Kanmatsuse K. Effect of pioglitazone on arteriosclerosis in comparison with that of glibenclamide. Diabetes Res Clin Pract. 2005;68(2):104–110.
    1. Lonn E, Yusuf S, Dzavik V, et al. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients with ramipril and vitamin E (SECURE) Circulation. 2001;103(7):919–925.
    1. Kaiser T, Heise T, Nosek L, Eckers U, Sawicki PT. Influence of nebivolol and enalapril on metabolic parameters and arterial stiffness in hypertensive type 2 diabetic patients. J Hypertens. 2006;24(7):1397–1403.
    1. Hosomi N, Mizushige K, Ohyama H, et al. Angiotensin-converting enzyme inhibition with enalapril slows progressive intima-media thickening of the common carotid artery in patients with non-insulin-dependent diabetes mellitus. Stroke. 2001;32(7):1539–1545.
    1. Manolis AJ, Iraklianou S, Pittaras A, et al. Arterial compliance changes in diabetic normotensive patients after angiotensin converting enzyme inhibition therapy. Am J Hypertens. 2005;18(1):18–22.
    1. Rahman S, Rahman T, Ismail AA, Ismail SB, Naing NN, Rahman ARA. Effect of Rosiglitazone and ramipril on preclinical vasculopathy in newly diagnosed, untreated T2DM and IGT patients: one-year randomised, double-blind and placebo-controlled study. Eur J Clin Pharmacol. 2007;63(8):733–741.
    1. Rahman S, Rahman T, Ismail AA, Ismail SB, Naing NN, Rahman ARA. Early manifestation of macrovasculopathy in newly diagnosed never treated type II diabetic patients with no traditional CVD risk factors. Diabetes Res Clin Pract. 2008;80(2):253–258.
    1. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457–2471.
    1. Marre M, Lievre M, Chatellier G, Mann JFE, Passa P, Ménard J. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study) BMJ. 2004;328(7438):495–499.
    1. HOPE Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: result of HOPE study and MICRO-HOPE substudy. Lancet. 2000;355(9200):253–259.
    1. American diabetic association. Standards of medical care for patients with diabetes mellitus (position statement) Diabetes Care. 1998;21(Suppl 1):s23–s31.
    1. Philips LS, Grunberger G, Miller E, Patwardham R, Rappaport EB, Salzman A. Once- and twice daily dosing of rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care. 2001;24(2):308–315.
    1. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of Rosiglitazone Treatment on Nontraditional Markers of Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus. Circulation. 2002;106(6):679–684.
    1. Fonseca VA, Valiquett TR, Huang SM, Ghazzi MN, Whitcomb RW. Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study. The Troglitazone Study Group. J Clin Endocrinol Metab. 1998;83(9):3169–3176.
    1. Aronoff S, Rosenblatt S, Braithwaite S. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care. 2000;23(11):1605–1611.
    1. Silvio E, Inzucchi MD. Oral anti hyperglycemic therapy for type 2 diabetes scientific review. JAMA. 2002;287(3):360–372.
    1. Girerd X, Giannattasio C, Moulin C, Safar M, Mancia G, Laurent S. Regression of radial artery wall hypertrophy and improvement of carotid artery compliance after long-term antihypertensive treatment in elderly patients. J Am Coll Cardiol. 1998;31(5):1064–1073.
    1. Roman MJ, Alderman MH, Pickering TG, et al. Differential effects of angiotensin converting enzyme inhibition and diuretic therapy on reductions in ambulatory blood pressure, left ventricular mass, and vascular hypertrophy. Am J Hypertens. 1998;11(4):387–396.
    1. Tropeano AI, Boutouyrie P, Pannier B, et al. Brachial pressure–independent reduction in carotid stiffness after long-term angiotensin-converting enzyme inhibition in diabetic hypertensives. Hypertension. 2006;48(1):80–86.
    1. Bosch J, Yusuf S, Pogue J, et al. Use of ramipril in preventing stroke: double blind randomised trial. BMJ. 2002;324(7339):699–702.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe